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In excitable tissues, voltage-dependent Na+ current (INa) is
best known for supporting autoregenerative depolarization
and impulse propagation. Its transient component (INaT),
which is large and terminated within several milliseconds
by channel inactivation, fulfils this role. Nevertheless, INa
also includes a smaller sustained component, i.e. one
persisting during prolonged membrane depolarization,
which contributes to repolarization course. Sustained INa
implies slow or incomplete inactivation of a proportion
of the Na+ channels activated during the action potential
upstroke. Several mechanisms may underlie this phenom-




Truly steady-state currents may flow through otherwise
inactivating channels if membrane potential is maintained
in a restricted range (“window”). These currents are com-
monly referred to as “window currents”. The window
corresponds to the region of overlap between “activation”
and “inactivation” curves, in which the probabilities of
channels to be open and not inactivated are both greater
than 0 at steady-state. A window is normally present in
cardiac myocytes for ICaL and, to a lesser extent for INa
(Fig. 1), but it may be enhanced, or shifted to different
potentials, by channel mutations (e.g. the Nav1.5 ΔKPQ
mutation) [1].
When, during repolarization, membrane potential moves
into the “window”, a fraction of channels may recover from
inactivation and immediately reactivate. The resulting depo-
larization supports autoregenerative activation which, albeit
concerning a small fraction of total channels, may substan-
tially distort membrane potential course (early afterdepola-
rizations, EADs) and even trigger propagated activity [2, 3].
The INa window is narrow and more negative than the
plateau phase in normal ventricular myocytes; thus, in the
latter ICaL window more likely accounts for EADs genera-
tion [4] (Fig. 1). INa window, somewhat more prominent in
normal Purkinje myocytes [5, 6], may be widened in all cell
types by Na+ channel mutations.
A further mechanism of INa enhancement during repolar-
ization is provided by an increase in the rate of channel
recovery from inactivation relative to deactivation one. This
mechanism, observed in some NaV1.5 mutations, is referred
to as “reactivation under non-equilibrium conditions” [7].
This is because the excess Na+ current can be observed only
during dynamic changes of membrane potential (non-equi-
librium). This is not a proper steady-state component and,
notably, it can escape detection by the standard “voltage
step” clamp protocols used to assess the functional pheno-
type of channel mutations.
Late Na+ Current (INaL)
Figure 2a shows that sustained INa, identified as current
sensitive to blockade by tetrodotoxin (TTX), exists also at
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potentials positive to the INa window (−65 to −50 mV;
shown in in Fig. 1a for the same cell type). This current is
provided by a component named “late” Na+ current (INaL).
INaL, much smaller than INaT in normal ventricular myo-
cytes, may be enhanced by more than 3-fold under patho-
logical conditions [8]. Single-channel analysis reveals that
the channel gating underlying INaL is complex and, in addi-
tion to late “scattered” openings, it includes a “burst mode”
not observed during the transient component of INa (INaT) [9,
10]. This led to hypothesize that INaL might be carried by
channel variants other than the one prevailing in cardiac
myocytes (NaV1.5), whose expression would be enhanced
under pathological conditions (a contribution of NaV1.8
channels to INaL in mouse and rabbit cardiomyocytes has
been indeed reported [11]). However, INaL with all its gating
modes, can be detected by expression of Nav1.5 channels in
cell lines (Fig. 2b), where no other Na+ channel isoforms are
present [10, 12]. This proves that INaL can be carried by the
same molecular entity accounting for INaT; according to this
view, INaL enhancement reflects a gating abnormality.
Observations crucial for the development of this interpreta-
tion came from single channel analysis of a mutation
(ΔKPQ) associated with LQT3 syndrome [13]. The mutant
channel had increased probability of burst openings during
sustained depolarization, a behaviour interpreted as instability
of the inactivated state [1, 13]. The interpretation of INaL
enhancement as a gating abnormality of Nav1.5 channels
may hold true also for acquired conditions, as proven in the
case of heart failure [14–16]. Nevertheless, we cannot rule out
that changes in isoform expression may contribute in some of
the diverse conditions in which INaL enhancement occurs.
Because of recovery from inactivation upon repolariza-
tion takes some time, INaT availability depends on the inter-
val between excitations. This is true also for INaL, thus
Fig. 1 Comparison of the membrane potential “window” for INa and
ICaL in rat ventricular myocytes. Steady-state activation and inactiva-
tion curves for INa (left) and ICaL (right). The “window”, i.e. the
membrane potential range in which activation and inactivation overlap,
is filled in grey. INa window (zoomed in the inset) is smaller and at
more negative potentials than ICaL one. (from Rocchetti et al.
unpublished)
Fig. 2 TTX-sensitive current (lower panels, largely representative of
INa) elicited by clamping the membrane with the action potential
waveform (upper panel) (AP-clamp); the inset in each panel shows
the dynamic I/V relation, obtained by plotting current as a function of
membrane potential. TTX-sensitive current flowing during repolariza-
tion includes all sustained Na+ components. a recording in a rat
myocyte, clamped with its own action potential (Rocchetti et al. un-
published); b recording in a cell line (HEK239) transfected with
NaV1.5 (α and β subunits) and clamped with a human ventricular
action potential (from ref [12], modified). INaT is truncated in all
recordings
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conferring to this current “reverse” rate-dependency [17],
which is partial at physiological rates (approx 50 % reduc-
tion from quiescence to 120 b/min) [18].
Mutations prolonging action potential duration (APD) cause
enhancement of plateau Na+ current through one or more of the
mechanisms described above. For instance, all the above (wid-
ened voltage window, inactivation instability and accelerated
recovery) may be operative in ΔKPQ mutants [1], but only
non-equilibrium reactivation appears to account for the APD
prolonging effect observed with the Il768V mutant [7].
Conditions and Mechanisms of INaL Enhancement
Although the interest in INaL pathophysiological role was
mostly triggered by identification of Na+ channel mutations
leading to arrhythmogenic QT prolongation [1], secondary
INaL enhancement occurs in association to a surprisingly
large number of common disease states (reviewed in [19]),
including cardiac hypertrophy/failure and ischemia, not nec-
essarily related to each other in terms of primary pathogen-
esis. Such a pattern suggests that INaL enhancement may be a
common response to cell stress/dysfunction. Accordingly, in
cardiac myocytes, INaL is enhanced by reactive oxygen species
(ROS) [20], whose generation is generally associated to cell
distress. The question of whether ischemia can enhance INaL
can be answered only indirectly, because membrane currents
can be recorded only in isolated myocytes, which cannot be
subjected to ischemia. Nevertheless, INaL is enhanced by
myocyte exposure to hypoxia [21] or ischemic metabolites
[22] and INaL blockade effectively prevents ischemia/reperfu-
sion damage in the intact heart [23].
The search of a common mechanism, mediating INaL en-
hancement by cellular stress of heterogeneous etiology, has
highlighted the role of Ca2+-calmodulin kinase (CaMKIIδ)
activation [24]. This is a Ca2+- and ROS-activated cytosolic
enzyme which may, among other targets, phosphorylates
NaV1.5 channels. Converging evidence indicates that CaM-
KIIδ overexpression (or activation) enhances INaL and gener-
ates cardiac abnormalities that are reversed by INaL blockade
[25]. Upstream components of the CaMKII activation path-
way, i.e. calmodulin (CaM) and Ca2+ itself, have also been
shown to enhance INaL directly, with differences between
normal and failing myocytes [26]. While this does not rule
out further modes of INaL enhancement (see ref [27]. for
review), CaMKIIδ activation is particularly relevant because
its relation with INaL may set up a vicious feed-back loop
(Fig. 3), very likely to contribute to evolution of cell dysfunc-
tion and damage in response to stress. Whereas CaMKII
inhibition is not available for therapeutic use yet, INaL block-
ade may break such a vicious loop [25].
To summarize, except for the case of primary (genetic)
Na+ channel defects, INaL enhancement might be viewed as
a generic response to cellular stress, that is secondary in
origin, but has a pivotal role in mediating functional
derangements and disease progression.
INaL enhancement can also result from abnormalities in
proteins other than the Na+ channel itself, but interacting
with it to form macromolecular complexes [28, 29]. For
instance, mutations of scaffold and adaptor proteins, as
ankyrin-B [30] and caveolin-3 [31] respectively, have been
recently identified in LQT3 patients. A detailed review of
the factors potentially contributing to INaL enhancement in
heart failure has been provided by Matsev et al. [27].
INaL Impact on Electrical Activity and Ionic Homeostasis
INaL directly affects electrical activity (it promotes depolar-
ization or counters repolarization) and provides a route of
Na+ influx. Considering the role of Na+ gradient in trans-
membrane transport, the latter may affect cellular solute
homeostasis, thus generating a host of indirect consequences
of physiological and pathophysiological relevance.
Electrophysiological Effects
INaL flows during repolarization and may directly affect its
course. In normal canine ventricles INaL is differentially
expressed across the wall (M-cells and Purkinje cells >
subendocardial cells > subepicardial cells) [17, 32, 33].
Thus, it is conceivably a player in the physiological trans-
mural repolarization gradient and in its rate-dependency in
Fig. 3 Network of events linking INaL enhancements to its pleiotropic
effects. Notably, many events are linked in positive feed back loops,
likely to amplify and sustain the network once it has been initiated.
Experimental observations (see text) suggest that INaL enhancement
and CaMKII activation are key elements in this process. Events in red
boxes imply increased ATP consumption, those in blue boxes reduced
oxygen supply
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the dog (APD restitution) [34]. In normal ventricular myo-
cytes, INaL inhibition by ranolazine (INa blocker with selec-
tivity for INaL vs INaT) causes negligible APD changes. On
the other hand, the remarkable effects of IKr blockade on
APD, on its rate-depencency and, most importantly, on
repolarization stability are all reversed by ranolazine [18,
35, 36]. These apparently contrasting findings may be rec-
onciled by considering that ranolazine also partially blocks
IKr [37]. Under basal conditions, this may offset the effect of
INaL inhibition on APD; in turn, concomitant INaL inhibition
limits the effect of IKr inhibition, thus preventing repolari-
zation instability. If this interpretation is correct, we can
conclude that INaL and IKr are physiologically in balance
during normal repolarization; whenever this balance is al-
tered, by either INaL enhancement or IKr blockade, repolar-
ization stability is compromised. An extreme example of
this condition is advanced heart failure, in which INaL en-
hancement and IKr downregulation coexist and are associat-
ed with dramatic repolarization instability [15]. Although
the concept of IKr - INaL balance is valid in a broad sense, the
effects of IKr blockade and INaL enhancement on action
potential contour are not identical, an observation which
may have its counterpart in the differences of clinical pre-
sentation between the LQT2 (IKr deficiency) and LQT3
(INaL enhancement) syndromes [38].
The direct contribution of INaL to repolarization course
provides a first powerful mechanism linking arrhythmogen-
esis to INaL enhancement. Nevertheless, the latter may also
facilitate arrhythmias through Ca2+ handling abnormalities
(see below) and it is difficult to establish which mechanism
prevails in a specific condition. The mutual interplay be-
tween Ca2+ handling and repolarization course [39] may
actually make this distinction pointless.
A role of INaL in arrhythmogenesis is often inferred from the
antiarrhythmic effect of its selective blocker ranolazine. While
this may be considered legitimate in many cases, there are
exceptions due to specificities of drug action. The best example
is ranolazine efficacy on atrial arrhythmias, to which mecha-
nisms other than INaL inhibition may also contribute [40].
Effects on Ionic Homeostasis
INa represents the main source of Na
+ entry during the
cardiac cycle. Abeit INaL amplitude is normally 1/1000 of
that of INaT [10], INaL persists throughout repolarization; as a
result, INaT and INaL may similarly contribute to Na
+ influx
during a cardiac cycle [41]. Nevertheless, INaL inhibition (by
TTX or ranolazine) marginally affects Ca2+ cycling [42] and
contractility [43] in normal hearts, thus suggesting that the
attending changes in Na+ influx are effectively buffered by
matching changes in Na+ extrusion. However, cellular ho-
meostasis can be compromised by the marked increase in
Na+ influx resulting from pathological INaL enhancement.
Na+ is normally extruded from the cell by the ATP powered
Na+/K+ pump. Therefore excess Na+ influx, even when suc-
cessfully buffered, may increase ATP consumption. Further-
more, if influx exceeds the maximal extrusion rate, Na+
accumulates in the cytosol, thus partially dissipating its trans-
membrane gradient. Because the latter energizes many sec-
ondary membrane transport mechanisms, most importantly
the Na+/Ca2+ exchanger (NCX) and the Na+/H+ exchanger
(NHE), a pivotal consequence of INaL enhancement is per-
turbed homeostasis of intracellular Ca2+ and H+ (Fig. 3).
NCX is the main mechanism of Ca2+ extrusion from the
cell. Increased cytosolic Na+ moves its electrochemical
equilibrium potential in the negative direction, thus reducing
the driving force for its forward operation during diastole
and possibly reversing the direction of transport during
systole (i.e. Ca2+ entry through NCX). The resulting in-
crease in intracellular Ca2+ may re-establish NCX driving
force, but the system equilibrium is now moved to higher
cytosolic Ca2+ levels. Under conditions of INaL enhance-
ment (e.g heart failure) NCX expression may be upregulated
[44] and, provided that a driving force still exists, this may
increase Ca2+ transport rate. However, the effect of this
change in sustaining Ca2+ extrusion can only be partial,
because it vanishes as NCX electrochemical equilibrium is
approached. Accordingly, unless maximal Na+/K+ pump
transport rate is also incremented, an increase in total cellu-
lar Ca2+ content is a necessary consequence of INaL enhance-
ment. A further aspect of interest is the distribution of such an
increment between subcellular compartments. Stimulation of
Ca2+ uptake by the sarcoplasmic reticulum (SR) (by
SERCA2) is a central component of physiological stimuli
meant to increase cell Ca2+ content (e.g. by β-adrenergic
activation). This ensures that most of the gain concerns SR
luminal Ca2+, which results in larger amplitude of Ca2+ tran-
sient (larger developed force) and lower diastolic Ca2+ (accel-
erated relaxation). This is not the case for INaL enhancement,
in which the Ca2+ increment concerns primarily the cytosol,
which may only secondarily increase Ca2+ in the SR. Al-
though the latter may increase maximal developed force, this
is expectedly associated with higher diastolic Ca2+. The con-
sequences of cytosolic Ca2+ being persistently elevated are
multiple and of pathophysiological relevance.
Opening of SR Ca2+ release channels (RyRs) is directly
triggered by cytosolic Ca2+, a process facilitated by high Ca2+
in the SR lumen [45]. Increased cytosolic Ca2+ also activates
CaMKII-dependent RyRs phosphorylation, a further mecha-
nism of RyRs facilitation (see below, Fig. 3). It is therefore
unsurprising that INaL enhancement may lead to facilitation of
diastolic “Ca2+ waves” and the resulting electrical disturban-
ces (delayed afterdepolarizations, DADs) [46]. This represents
an important arrhythmogenic mechanism, probably the
one prevailing under conditions of altered Ca2+ handling
(e.g. heart failure).
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With persistently elevated cytosolic Ca2+, diastolic func-
tion may be hampered by delayed and incomplete sarcomere
relaxation. A contribution of INaL to diastolic dysfunction
has been demonstrated in various experimental models of
heart failure [25, 42] and ranolazine improved diastolic
relaxation in human ischemic heart disease [47]. In addition
to its direct hemodynamic impact, diastolic dysfunction may
limit coronary flow by extrinsic compression of intramural
vessels. Significance of this effect is indirectly demonstrated
by the ability of ranolazine to improve myocardial perfusion
in the setting of coronary artery disease (likely INaL en-
hancement) [48]. Indeed, being ranolazine devoid of signif-
icant direct vasodilator effects, the perfusion improvement is
likely to result from accelerated diastolic relaxation, a well
known factor in modulation of coronary flow [49].
Abnormally elevated cytosolic Ca2+ may also activate a
number of signalling pathways involved in modulation of cell
function and, in the long run, structure and fate. CaMKIIδ
activation, is at the same time, a cause (see above) and a
consequence [50] of INaL enhancement. Phosphorylation of
SR Ca2+ release channels (RyRs) by this kinase increases their
open probability [51], ultimately leading to destabilization of
the Ca2+ store. This accounts for the facilitation of spontaneous
Ca2+ release events and delayed afterpotentials (DADs, their
arrhythmogenic electrical consequence) induced by either INaL
enhancement or CaMKIIδ overexpression [52] and suppressed
in both cases by INaL blockade [25]. Calcineurin, a cytosolic
Ca2+-activated phosphatase, regulates translocation to the nu-
cleus of NFAT, a transcriptional regulator centrally involved in
hypertrophic remodelling [53]. While there is still no direct
evidence for the involvement of this specific pathway in INaL-
induced damage, ranolazine has been shown to affect down-
stream gene transcription and histomorphometric parameters
in heart failure induced by coronary microembolization [54].
A further consequence of pathological INaL enhancement is
a derangement in cell energy balance. The main ATP-
consuming mechanism involved in the control of cellular
homeostasis (the Na+/K+ and SERCA pumps) are conceivably
short-circuited by enhanced sarcolemmal Na+ influx and in-
creased Ca2+ leak from the SR (by RyRs facilitation) (Fig. 3).
Therefore, INaL enhancement is expected to increase ATP
consumption by mechanisms not directly involved in force
generation, which would translate into decreased mechanical
efficiency. This view is supported by the observation that INaL
blockade prevents the drop in myocardial ATP, but not the
positive inotropic effect, of ouabain [55]. In addition to im-
proved coronary perfusion, increased myocardial efficiency
might partly account for the ability of INaL blockade to im-
prove exercise capacity of ischemic patients without altering
systolic mechanical work [56].
It has been reported that increased cytosolic Na+ may also
jeopardize mitochondrial function (Fig. 4). Concomitant cy-
tosolic Na+ loading (to 15 mM) impaired Ca2+-triggered
mitochondrial energetic adaptation in patch-clamped myo-
cytes, thereby causing an abnormal drop in NADH (i.e met-
abolic energy) upon catecholamine challenge [57]. On the
other hand, ranolazine pre-treatment failed to modify NADH
course during global ischemia/reperfusion in isolated hearts
[43]. Notably, in the same preparation, ranolazine opposed
ischemia-induced rise in cytosolic and mitochondrial Ca2+;
this was associated, as expected, with diminished ROS gen-
eration and delayed opening of mitochondrial permeability
transition pore (mPTP) [43]. A plausible network of mecha-
nisms in accord with these observations is illustrated in Fig. 4.
Altogether, this preliminary evidence suggests that, during
ischemia/reperfusion, INaL inhibition may be more effective
in preserving integrity of mitochondria than in improving their
function. Although ranolazine effects on energy metabolism
can be accounted for by INaL inhibition, the drug has been also
reported to inhibit fatty acid oxidation [58, 59], a further action
potentially protecting mitochondria during metabolic stress.
Fig. 4 A plausible sequence of events coupling INaL enhancement to
mitochondrial damage. Functions primarily depressed upon INaL en-
hancement are in purple, those upregulated to compensate in yellow.
Elevated cytosolic Ca2+ (Cacyt) loads the mitochondria through the Ca
2+
uniporter (MCU) and stimulates NADH production by the tricarboxilic
acids (TCA) cycle. Excess mitochondrial Ca2+ is partially removed by
mitochondrial NCX (mNCX), driven by high cytosolic Na+ [57]. This
chain of events (in the dotted box) results in positive charge influx,
which tends to dissipate the electrical gradient (Ψm) that drives ATP
synthesis by the ATP-synthase (F1F0) [64]. The resulting drop in the
ATP/ADP ratio is compensated by increasing the electron transport rate
(by ETC), fuelled by NADH [57]. In this scheme NADH and ATP
levels may be preserved up to a limit [57], but at the cost of increased
substrate consumption and ROS production by ETC [43]. Concomi-
tantly elevated mitochondrial Ca2+ and ROS facilitate opening of mPTP
[43], eventually resulting in loss of membrane selectivity, swelling and
disruption of the outer mitochondrial membrane. Release of cyro-
chrome C and other components of the outer membrane space triggers
cell apoptosis [64]
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However, this action was observed with drug dosage (60–
200 mg/Kg/day) far from that required for the anti-ischemic
effect in humans (10–15 mg/Kg/day).
Under normal conditions, cellular H+ homeostasis may
be less sensitive than Ca2+ homeostasis to INaL enhance-
ment, because mechanisms other than NHE contribute to H+
extrusion. During abrupt reperfusion following acute coro-
nary occlusion, massive H+ extrusion through NHE contrib-
utes to intracellular Na+ loading, which explains why direct
NHE inhibition paradoxically improves Ca2+ handling and
limits myocardial injury [60]. Nevertheless, the situation
might be different in the presence of chronic partial ische-
mia, when reduced H+ export by NHE might lead to persis-
tent intracellular acidosis, potentially contributing to impair
force development and relaxation. Although awaiting exper-
imental confirmation, this hypothesis is supported by the
observation that the increment in intracellular Na+ caused by
Na+/K+ pump blockade does produce intracellular acidosis,
which can be prevented by concomitant INaL blockade [55].
Functional Interaction Between INaL and K
+ Currents
Several observations suggest a complex interplay, with part-
ly unexplained mechanisms, between INaL and K
+ currents
during repolarization. Such an interplay may have conse-
quences on electrophysiology and ionic homeostasis.
The impact on repolarization of blocking endogenous INaL
in the presence of K+ current inhibition (IKr, Ito or IK1) [36]
may look disproportionately large to the small magnitude of
the inward current removed by INaL block. Although ranola-
zine, often used as the INaL blocker, shares the channel binding
domain on HERG channels (carrying IKr) with E-4031, it
cannot competitively displace E-4031 [36]. Moreover, rano-
lazine effects are largely mimicked by TTX, which does not
bind to HERG channels. Therefore, this disproportion cannot
be attributed to ancillary ranolazine properties and remains
largely unexplained.
A further relevant aspect of INaL blockade is its ability to
interfere with the intrinsic reverse rate-dependency of APD
and of its amplification by K+ channel blockers [18]. Be-
cause INaL decreases at faster rates (see above), INaL block
shortens APD more at slower ones, thus dampening the
intrinsic reverse rate-dependency of repolarization [18].
Rate-dependency of INaL may also account for the ability
of INaL block to flatten “APD restitution” curves, an action
strongly correlated with antifibrillatory effect [34].
Recent work on olfactory neurons highlights a structur-
ally organized relationship between Na+ channels and the
Na+-activated K+ current (IKNa) [61], whereby the latter is
specifically activated by Na+ influx through INaL. IKNa acti-
vation may oppose INaL-induced membrane depolarization
but, by doing this, it would increases the driving force for
Na+ influx. Thus, coupling to IKNa might partially dissociate
the effects of INaL enhancement on membrane potential from
those on intracellular ionic homeostasis. IKNa is expressed in
(guinea-pig) ventricular myocytes [62] and contributes to
regulate APD [63]. However, its structural association with
cardiac INa channels and functional interaction with INaL
enhancement has not been investigated thus far.
Conclusions
Although of small magnitude, endogenous INaL contributes
in setting repolarization course of normal myocytes, being
in a delicate balance with K+ currents. Disruption of this
balance may strongly affect repolarization and its stability.
Furthermore, INaL enhancement, occurring in many patho-
logical conditions as a general response to cell stress, can
profoundly alter intracellular ionic homeostasis with conse-
quences on contractile function, electrical stability and cell
fate. Accordingly, INaL represents a therapeutic target with
an expectedly pleiotropic effect, which is being gradually
unveiled by experimental and clinical studies.
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